ARQT Arcutis Biotherapeutics Forecast, Technical & Fundamental Analysis
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs... Show more
ARQT is expected to report earnings to fall 18.27% to 8 cents per share on October 29
Q3'26
Est.
$0.09
Q2'26
Beat
by $0.07
Q1'26
Missed
by $0.04
Q4'25
Beat
by $0.05
Q3'25
Beat
by $0.15
The last earnings report on August 05 showed earnings per share of 10 cents, beating the estimate of 3 cents. With 588.88K shares outstanding, the current market capitalization sits at 2.97B.
A.I. Advisor
published General Information
General Information
a company, which engages in the development and commercialization of treatments for dermatological diseases.
A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with XNCR. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then XNCR could also see price increases.
ARQT in downward trend: 10-day moving average moved below 50-day moving average on August 13, 2026
The 10-day moving average for ARQT crossed bearishly below the 50-day moving average on August 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARQT as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
ARQT moved below its 50-day moving average on August 19, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ARQT entered a downward trend on August 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in of 296 cases, the price rose further within the following month. The odds of a continued upward trend are .
ARQT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.477) is normal, around the industry mean (20.583). P/E Ratio (107.545) is within average values for comparable stocks, (27.923). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.559). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (6.729) is also within normal values, averaging (443.835).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
